These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 30639257)

  • 1. Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers.
    Zhao Z; Ukidve A; Krishnan V; Mitragotri S
    Adv Drug Deliv Rev; 2019 Mar; 143():3-21. PubMed ID: 30639257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silica-Based Nanoparticles for Biomedical Applications: From Nanocarriers to Biomodulators.
    Yang Y; Zhang M; Song H; Yu C
    Acc Chem Res; 2020 Aug; 53(8):1545-1556. PubMed ID: 32667182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicological Concerns of Engineered Nanosize Drug Delivery Systems.
    Mukherjee B; Maji R; Roychowdhury S; Ghosh S
    Am J Ther; 2016; 23(1):e139-50. PubMed ID: 24100254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polysaccharides as nanocarriers for therapeutic applications.
    Singh D; Han SS; Shin EJ
    J Biomed Nanotechnol; 2014 Sep; 10(9):2149-72. PubMed ID: 25992452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement.
    Shen J; Sun M; Ping Q; Ying Z; Liu W
    Nanotechnology; 2010 Jan; 21(2):025101. PubMed ID: 19955616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The fate of nanocarriers as nanomedicines in vivo: important considerations and biological barriers to overcome.
    Moros M; Mitchell SG; Grazú V; de la Fuente JM
    Curr Med Chem; 2013; 20(22):2759-78. PubMed ID: 23627938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoformulation properties, characterization, and behavior in complex biological matrices: Challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential.
    Agrahari V; Burnouf PA; Burnouf T; Agrahari V
    Adv Drug Deliv Rev; 2019 Aug; 148():146-180. PubMed ID: 30797956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface modification of nonviral nanocarriers for enhanced gene delivery.
    Fortier C; Durocher Y; De Crescenzo G
    Nanomedicine (Lond); 2014 Jan; 9(1):135-51. PubMed ID: 24354815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments.
    Yu HP; Aljuffali IA; Fang JY
    Curr Pharm Des; 2017; 23(3):481-494. PubMed ID: 28292243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of drug molecular weight on self-assembly and intestinal permeation of polymer-based nanocarriers.
    Schreiner J; Rindt C; Wächter J; Jung N; Vogel-Kindgen S; Windbergs M
    Int J Pharm; 2023 Nov; 646():123483. PubMed ID: 37802258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responsive Nanocarriers as an Emerging Platform for Cascaded Delivery of Nucleic Acids to Cancer.
    Liu Y; Xu CF; Iqbal S; Yang XZ; Wang J
    Adv Drug Deliv Rev; 2017 Jun; 115():98-114. PubMed ID: 28396204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-loaded nanocarriers: passive targeting and crossing of biological barriers.
    Rabanel JM; Aoun V; Elkin I; Mokhtar M; Hildgen P
    Curr Med Chem; 2012; 19(19):3070-102. PubMed ID: 22612696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.
    Du JZ; Li HJ; Wang J
    Acc Chem Res; 2018 Nov; 51(11):2848-2856. PubMed ID: 30346728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of nanoparticle shape in cancer drug delivery.
    Truong NP; Whittaker MR; Mak CW; Davis TP
    Expert Opin Drug Deliv; 2015 Jan; 12(1):129-42. PubMed ID: 25138827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanocarriers with tunable surface properties to unblock bottlenecks in systemic drug and gene delivery.
    Zou H; Wang Z; Feng M
    J Control Release; 2015 Sep; 214():121-33. PubMed ID: 26208425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicochemical properties, pharmacokinetics, toxicology and application of nanocarriers.
    Cai X; Jin M; Yao L; He B; Ahmed S; Safdar W; Ahmad I; Cheng DB; Lei Z; Sun T
    J Mater Chem B; 2023 Jan; 11(4):716-733. PubMed ID: 36594785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of surface modification and size on oral drug delivery of mesoporous silica formulation.
    Wang Y; Cui Y; Zhao Y; Zhao Q; He B; Zhang Q; Wang S
    J Colloid Interface Sci; 2018 Mar; 513():736-747. PubMed ID: 29220688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium phosphate nanocarriers for drug delivery to tumors: imaging, therapy and theranostics.
    Huang D; He B; Mi P
    Biomater Sci; 2019 Oct; 7(10):3942-3960. PubMed ID: 31414096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of porous silicon nanocarriers for parenteral peptide delivery.
    Kovalainen M; Mönkäre J; Kaasalainen M; Riikonen J; Lehto VP; Salonen J; Herzig KH; Järvinen K
    Mol Pharm; 2013 Jan; 10(1):353-9. PubMed ID: 23186283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of protein corona on in vivo fate of nanocarriers.
    Xiao Q; Zoulikha M; Qiu M; Teng C; Lin C; Li X; Sallam MA; Xu Q; He W
    Adv Drug Deliv Rev; 2022 Jul; 186():114356. PubMed ID: 35595022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.